API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.asiaone.com/business/kintor-pharma-and-etanas-collaboration-pruxelutamides-covid-19-project-awarded-belt-and
https://www.prnewswire.com/news-releases/kintor-pharmas-proxalutamide-demonstrated-reduction-in-hospitalizationmortality-for-patients-with-mild-to-moderate-covid-19-in-phase-iii-mrct-study-301518525.html
https://www.prnewswire.com/news-releases/kintor-pharma-announces-first-patient-dosing-in-china-in-phase-iii-clinical-trial-of-proxalutamide-for-the-treatment-of-covid-19-outpatients-301480612.html
https://www.reuters.com/article/us-health-coronavirus-kintor-pharm/chinas-kintor-says-interim-analysis-of-covid-treatment-trial-misses-statistical-criteria-idUSKBN2J60NV
https://www.prnewswire.com/news-releases/kintor-pharma-announces-first-patient-dosing-in-phase-iii-clinical-trial-of-proxalutamide-for-the-treatment-of-hospitalized-covid-19-patients-in-us-301391565.html
https://www.biospectrumasia.com/news/25/18901/chinese-pharma-to-commercialize-proxalutamide-for-covid-19-treatment-in-indonesia.html#:~:text=Kintor%20Pharmaceutical%20Limited%2C%20a%20clinical,of%20COVID%2D19%20in%20Indonesia.
https://www.prnewswire.com/news-releases/completion-of-patients-recruitment-for-proxalutamides-covid-19-hospitalised-study-301232337.html
https://www.clinicaltrialsarena.com/news/brazil-proxalutamide-trial-kintor/
https://www.prnewswire.com/news-releases/kintor-proxalutamides-covid-19-clinical-trial-shows-significant-reduction-in-hospitalization-and-ventilation-rates-301191525.html
https://www.biospace.com/article/releases/kintor-pharmaceutical-s-covid-19-clinical-trials-for-proxalutamide-to-expand-patient-enrolment/
https://endpts.com/kintor-pharmaceuticals-completes-240-million-ipo-wuxi-biologics-is-opening-a-boston-plant/